ENTITY
Antengene

Antengene (6996 HK)

44
Analysis
Health CareChina
Antengene Corporation Limited operates as a specialty pharmaceutical company. The Company produces innovative drugs, selinexor, eltanexor, verdinexor, and other products. Antengene provides its services throughout China.
more
24 Oct 2023 23:09

Hansoh Pharmaceutical (3692 HK): New Licensing Deal Boosts Conviction on Innovative Pipeline Prowess

​Hansoh Pharma will receive an upfront payment of $85M and potential milestone payments of up to $1.485B. The licensed drug candidate is currently...

Logo
520 Views
Share
bearishLaekna
14 Jun 2023 08:55

Pre-IPO Laekna (PHIP Updates) - Some Key Points Worth the Attention

Laekna's core products would face different challenges, which makes us hard to be optimistic about their prospects.As a biotech based on license-in...

Logo
372 Views
Share
25 May 2023 08:55

Pre-IPO Cutia Therapeutics (CUT HK) - Outlook Is Uncertain Due to Unique Pipeline Characteristics

Cutia need to clarify whether its positioning is to sell drugs or consumer products,as their strategies will be different. Cutia has to strengthen...

Logo
302 Views
Share
25 Feb 2023 16:00

HSCI Index Rebalance: 35 Adds, 28 Deletes & Changes to Southbound Stock Connect

There are 35 adds & 28 deletes for the HSCI in March leading to 29 adds & 20 deletes for Stock Connect. 19 index constituents could be dropped from...

Logo
639 Views
Share
bullishJW Therapeutics
23 Jan 2023 09:26

China Healthcare Weekly (Jan.20) - NRDL Negotiation Results, JW Therapeutics, Sirnaomics, Antengene

We analyzed 2022 NRDL negotiation result - There're positive sides.The "safety pad" brought by medical insurance coverage may not be high.We...

Logo
434 Views
Share
x